YaoGeJu

Company directoryChina company filings

Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.

As of 18 November 2026, for the company name Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. as recorded, the chemical-drug catalogue lists 23 active records with this name as holder; 13 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

28 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Dapoxetine Hydrochloride Tablets 2 records · Latest accepted 2024/08/13

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402619Generic2024/08/13Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHS2402618Generic2024/08/13Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Temozolomide For Injection 3 records · Latest accepted 2023/11/29

Supplement · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2302623Supplement2023/11/29Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Guangdong Sunho Pharmaceutical Co., Ltd.CDE ↗
CYHB2302577Supplement2023/11/22Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Guangdong Sunho Pharmaceutical Co., Ltd.CDE ↗
CYHB2301699Supplement2023/07/29Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Guangdong Sunho Pharmaceutical Co., Ltd.CDE ↗
Sildenafil Citrate Tablets 3 records · Latest accepted 2023/07/26

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301992Generic2023/07/26Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHS2201973Generic2022/11/14Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHS2201972Generic2022/11/14Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Avanafil Tablets 3 records · Latest accepted 2023/07/11

Supplement · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2301538Supplement2023/07/11Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHB2301537Supplement2023/07/11Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHB2301536Supplement2023/07/11Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Metformin Hydrochloride And Empagliflozin Extended Release Tablets 4 records · Latest accepted 2023/05/17

Generic · 4

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301339Generic2023/05/17Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHS2301338Generic2023/05/17Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHS2301337Generic2023/05/17Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHS2301336Generic2023/05/17Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Tadalafil Tablets 3 records · Latest accepted 2023/04/28

Supplement · 1Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2300923Supplement2023/04/28Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHS2102033Generic2021/11/19Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHS2101582Generic2021/08/16Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Sivelestat Sodium for Injection 2 records · Latest accepted 2023/04/11

New drug · 1Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXHL2300361New drug2023/04/11Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
CYHB2100247Supplement2021/02/11Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Suzhou Erye Pharmaceutical Co., LtdCDE ↗
Azilsartan and Amlodipine Tablets 1 records · Latest accepted 2022/08/17

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHL2200066Generic2022/08/17Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Sugammadex Sodium Injection 2 records · Latest accepted 2022/08/01

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2201201Generic2022/08/01Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Suzhou Tianma Pharmaceutical Group Tianji biopharmaceutical Co., LtdCDE ↗
CYHS2201200Generic2022/08/01Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Suzhou Tianma Pharmaceutical Group Tianji biopharmaceutical Co., LtdCDE ↗
Esomeprazole Sodium for Injection 2 records · Latest accepted 2022/06/29

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2201057Supplement2022/06/29Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHB2201056Supplement2022/06/29Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Wuxi Kai Fu Pharmaceutical Co., Ltd. romanizedCDE ↗
Tenofovir Disoproxil Fumarate Tablets 1 records · Latest accepted 2021/11/25

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2102178Supplement2021/11/25Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Levoleucovorin for Injection 2 records · Latest accepted 2021/05/06

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXHB2101018Supplement2021/05/06Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Suzhou Di Yi Pharmaceutical Co., Ltd. romanizedCDE ↗
CXHB2101017Supplement2021/05/06Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.; Suzhou Di Yi Pharmaceutical Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Catalogue holder records

23 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Dapoxetine Hydrochloride TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202560012025/11/18Generic approved under the new chemical-drug registration classificationCDE ↗
Dapoxetine Hydrochloride TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202560002025/11/18Generic approved under the new chemical-drug registration classificationCDE ↗
Sildenafil Citrate TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202444592024/07/16Generic approved under the new chemical-drug registration classificationCDE ↗
Sugammadex Sodium InjectionShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Suzhou Tianma Pharmaceutical Group Tianji biopharmaceutical Co., Ltd国药准字H202435622024/04/24Generic approved under the new chemical-drug registration classificationCDE ↗
Sildenafil Citrate TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202435142024/04/17Generic approved under the new chemical-drug registration classificationCDE ↗
Sildenafil Citrate TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202435132024/04/17Generic approved under the new chemical-drug registration classificationCDE ↗
Tadalafil TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202470362024/02/29Generic approved under the new chemical-drug registration classificationCDE ↗
Tadalafil TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202332352023/02/28Generic approved under the new chemical-drug registration classificationCDE ↗
Tadalafil TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202332402023/02/28Generic approved under the new chemical-drug registration classificationCDE ↗
Esomeprazole Sodium for InjectionShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202030962022/03/25Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Esomeprazole Sodium for InjectionShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Wuxi Kai Fu Pharmaceutical Co., Ltd. romanized国药准字H202270402022/03/25Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Temozolomide For InjectionShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Sichuan Huiyu Pharmaceutical Co., Ltd.国药准字H202137242021/09/13Generic approved under the new chemical-drug registration classificationCDE ↗
Silodosin CapsulesShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202136122021/07/28Generic approved under the new chemical-drug registration classificationCDE ↗
Azacitidine For InjectionShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Sichuan Hui Yu Pharmaceutical Co., Ltd. romanized国药准字H202134932021/06/16Generic approved under the new chemical-drug registration classificationCDE ↗
Dienogest TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Nanjing Bai Jing Yu Pharmaceutical Co., Ltd. romanized国药准字H202134392021/06/01Generic approved under the new chemical-drug registration classificationCDE ↗
Avanafil TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202133382021/05/11Generic approved under the new chemical-drug registration classificationCDE ↗
Avanafil TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202133372021/05/11Generic approved under the new chemical-drug registration classificationCDE ↗
Avanafil TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202133362021/05/11Generic approved under the new chemical-drug registration classificationCDE ↗
Rivaroxaban TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202037402020/12/29Generic approved under the new chemical-drug registration classificationCDE ↗
Rivaroxaban TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202037392020/12/29Generic approved under the new chemical-drug registration classificationCDE ↗
Rivaroxaban TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H202037382020/12/29Generic approved under the new chemical-drug registration classificationCDE ↗
Tenofovir Disoproxil Fumarate TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H201934332019/12/30Generic approved under the new chemical-drug registration classificationCDE ↗
Ticagrelor TabletsShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.国药准字H201932522019/09/05Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

13 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
瑞卢戈利 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20260000272I2026/04/22CDE ↗
枸橼酸西地那非 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20240000285A2025/07/31CDE ↗
JC242 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20240000042I2024/01/29CDE ↗
舒更葡糖钠 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20220000464A2026/01/06CDE ↗
赛洛多辛 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20200000376A2026/10/21CDE ↗
HTMC0435 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20190001126I2019/12/16CDE ↗
西维来司他钠 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20190001060A2026/10/21CDE ↗
富马酸替诺福韦二吡呋酯 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20190006796A2023/03/24CDE ↗
阿伐那非 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20190000743A2025/12/03CDE ↗
替莫唑胺 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20180001446A2026/05/22CDE ↗
阿扎胞苷 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20180000608A2026/04/04CDE ↗
左亚叶酸 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20180001732A2026/03/21CDE ↗
艾司奥美拉唑钠 · No verified English nameShanghai Huilun Jiangsu Pharmaceutical Co., Ltd.Y20170001052A2023/11/23CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

9 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Relugolix Tablets CYHS2601163Generic2026/05/18Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
恩格列净二甲双胍缓释片(III) · No verified English name CYHB2500494Supplement2025/03/12Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
恩格列净二甲双胍缓释片(II) · No verified English name CYHB2500493Supplement2025/03/12Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
恩格列净二甲双胍缓释片(I) · No verified English name CYHB2500492Supplement2025/03/12Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Azilsartan and Amlodipine Tablets CYHS2402787Generic2024/08/27Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Metformin Hydrochloride And Empagliflozin Extended Release Tablets CYHB2401229Supplement2024/08/09Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Avanafil Tablets CYHB2202295Supplement2022/12/27Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Avanafil Tablets CYHB2202294Supplement2022/12/27Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗
Avanafil Tablets CYHB2202293Supplement2022/12/27Shanghai Hui Lun Pharmaceuticals Co., Ltd. romanized; Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.CDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.